AChE

The FDA ( U.S. Food and Drug Administration ) has approved Cablivi ( Caplacizumab-yhdp ) in combination with plasma exchange...


The FDA ( U.S. Food and Drug Administration ) has approved Mayzent ( Siponimod ) tablets to treat adults with...


The FDA ( U.S. Food and Drug Administration ) has approved Dovato ( Dolutegravir and Lamivudine ), as a complete...


The European Commission ( EC ) has approved Skyrizi ( Risankizumab ) for the treatment of moderate to severe plaque...


The FDA ( Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with...


The U.S. Food and Drug Administration ( FDA ) has approved Venclexta ( Venetoclax ) in combination with Obinutuzumab (...


The US Food and Drug Administration ( FDA ) has approved Bavencio ( Avelumab ) in combination with Inlyta (...


Results from the phase 3 TITAN study were presented in an oral session at the American Society of Clinical...


The European Commission ( EC ) has approved Lynparza ( Olaparib ) as a 1st-line maintenance treatment for women with...


Dacomitinib is an irreversible, pan-epidermal growth factor receptor ( HER ) inhibitor. The goal of a study was to evaluate the...


The FDA ( U.S. Food and Drug Administration ) has approved Biktarvy ( Bictegravir 50mg / Emtricitabine 200mg / Tenofovir...


Evidence suggests that atrial fibrillation ( AF ) is associated with a higher risk for cognitive impairment and dementia, with...


Since the precise mechanism(s) of cognitive disorders in patients with atrial fibrillation ( AF ) is not fully known, the...


The U.S. Food and Drug Administration ( FDA ) has approved Tafinlar ( Dabrafenib ) and ( Trametinib ), administered...


Dulaglutide ( Trulicity ) significantly improves A1C ( average blood sugar concentration over two to three months ) when added...


The European Medicines Agency ( EMA ) has approved Lynparza ( Olaparib ) tablets ( 300mg twice daily ) for...


The European Commission has approved a label update for the use of once-daily Relvar Ellipta ( Fluticasone furoate / Vilanterol,...


Triple-negative breast cancer ( TNBC ) is an aggressive subtype of breast cancer, often resistant to standard of care therapies....


The phase 2 ATLANTIC study has investigated the anti-PD-L1 antibody Durvalumab ( Imfinzi ) in heavily pretreated patients with advanced...


Guidelines strongly recommend patients with heart failure with reduced ejection fraction ( HFrEF ) be treated with multiple medications proven...